One recent phase III trial reported that HDAC inhibitors exemestane and entinostat did not improve survival in patients with aromatase inhibitor-resistant advanced BC although pharmacodynamic analysis confirmed target inhibition of HDACi (44). This evidence concerns the gene CYP19A1 and breast cancer.